ArticleLung India : official organ of Indian Chest Society2026
Phenotyping and unmet need assessment for biological agents in uncontrolled asthma.
Article in Lung India : official organ of Indian Chest Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
settingUncontrolled asthma patients at a university teaching hospital in India.
objectiveTo determine the prevalence, endotypes, and need for add-on therapies in severe asthma.
methodsThis prospective study screened all patients with uncontrolled asthma, and those with uncontrolled asthma while on moderate-to-high dose inhaled corticosteroids with long-acting beta agonists (ICS + LABA) were further assessed. Endotyping and optimisation of therapy for all potentially modifiable factors were performed, followed by reassessment at 3 months of optimised treatment. Uncontrolled patients at 3 months were classified as having severe asthma and assessed for eligibility for add-on therapies.
resultsAfter screening 261 uncontrolled asthma patients, 160 patients with uncontrolled asthma on moderate-high dose ICS + LABA were included in the study (prevalence of difficult-to-treat asthma: 61.2%). On endotyping, 134 (83.75%) had T2-high endotype and 26 (16.25%) had T2-low endotype asthma. Severe asthma prevalence was 20% (32 out of 160) in this subgroup, and they were assessed for eligibility for guideline-directed add-on therapy: 12 (37.5%) were eligible for omalizumab; 18 (56.25%) were eligible for mepolizumab, benralizumab, or dupilumab; and seven (21.87%) were not eligible for any add-on therapy.
conclusionT2-high asthma is five times more common than T2-low asthma, and the prevalence of severe asthma is 20% among uncontrolled asthmatics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.